TY - JOUR T1 - The author and colleagues reply: Bueno JF - New England Journal of Medicine Y1 - 2016 A1 - Dimopoulos, M.A. A1 - Sonneveld, P. A1 - Sun, H. VL - 375 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007099165&doi=10.1056%2fNEJMc1613868&partnerID=40&md5=cdb6cedb6f2d5ee648f6b23f6ba3ad77 IS - 25 N1 - Export Date: 18 February 2017References: Murphy, M.F., Dumont, L.J., Greinacher, A., Interference of new drugs with compatibility testing for blood transfusion (2016) N Engl J Med, 375, pp. 295-296;(2016) Summary of Product Characteristics: DARZALEX 20 mg/mL Concentrate for Solution for Infusion, , http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf, London: European Medicines Agency; Regan, D.M., Markowitz, M.A., Mitigating the anti-CD38 interference with serologic testing (2016) AABB Bulletin #16-02, , Bethesda, MD:American Association of Blood Banks; Palumbo, A., Chanan-Khan, A., Weisel, K., Daratumumab, bortezomib, and dexamethasone for multiple myeloma (2016) N Engl J Med, 375, pp. 754-766 ER -